BSH 2015

Professor Peter Hillmen speaks to ecancertv at BSH 2015 Edinburgh. Having chaired a talk at BSH, Prof Hillmen speaks about some of the key topics about Mantle cell lymphoma (MCL) and Chronic lymphocytic leukaemia (CLL) discussed by speakers Dr George Follows and Prof Simon Rule.

Dr Follows talks to ecancertv at BSH 2015 in Edinburgh. Dr Follows speaks about his phase II study using copanlisib to treat patients with aggressive non-hodgkin's lymphoma (NHL) and chronic lymphocytic leukaemia (CLL). He also speaks about future treatments using clever trial design with personalised treatments, combination therapies and chemotherapy.

Dr Emilio Cosimo speaks to ecancertv at BSH 2015 in Edinburgh. Dr Cosimo discusses the use of dual mTOR inhibition as an effective therapeutic approach for reducing tumour load in chronic lymphocytic leukaemia (CLL). He also speaks about the data showing inhibition in phosphoinositide 3-kinase (PIK3) and bruton's tyrosine kinase (BTK) through drugs such as idelalisib and ibrutinib. He warns of the evidence showing increased resistance to these drugs, concluding that the dual mTOR inhibition is a good alternative treatment singularly or in combination.

Dr Paul Fields (Guy's and St Thomas' Hospital, London, UK) and Dr Andrew Davies (University Hospital Southampton NHS Foundation Trust, Southampton, UK) discuss developing treatments in non hodgkin lymphoma at BSH 2015. They cover the current developments and evolving drugs, inhibitors, and their thoughts and opinions regarding ethics and toxicity of the treatments.

Dr Simon Noble speaks to ecancertv at BSH 2015 Edinburgh. Dr Noble discusses putting the patient at the centre of cancer-associated thrombosis treatment decisions, personalising the therapy based on the patient's experiences and deciding the best way to move forward.

Dr George Follows (Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK) and Professor Peter Hillmen (Leeds Teaching Hospitals NHS Trust, Leeds, UK) examine the recent outcomes of CLL trials at BSH 2015. They compare results of recent trials and discuss the challenges faced with these new therapies with a focus on the patients in the '116' randomised phase three trial receiving idelalisib plus rituximab.

Dr Claire Dearden speaks to ecancertv at BSH 2015 about her 350 patient phase III trial evaluating ibrutinib versus ofatumumab as a treatment for chronic lymphocytic leukaemia (CLL). She discusses the experimental oral therapy ibrutinib, which produces dramatic responses but avoids the significant toxicity seen in conventional treatments for chronic lymphocytic leukaemia and small lymphocytic lymphoma.

Dr Davies talks to ecancertv at BSH 2015 about novel approaches to the treatment of large B-cell lymphoma. He discusses some of the new drugs that are available and how it is now possible to divide patients into subsets based on the molecular biology of their illness and treat them with personalised medicine.

Dr Nita Prasannan speaks to ecancertv at BSH 2015 in Edinburgh. Dr Prasannan discusses using a virtual learning environment as an innovative high quality tool to provide laboratory training for haematology registrars. She talks about the necessity to standardise laboratory training across the country, with shift patterns and centralisation of laboratories being defining factors that reflect unfairly in exit exams.

Dr Charlotte Brierley talks to ecancertv at BSH 2015 about iron status in paediatric acute lymphoblastic leukaemia. Dr Brierley discusses recent studies involving a clinical cohort of children monitoring whether the transfusion burden they received during therapy had any long term implications, specifically focusing on the extent that the patients were affected by iron burden or iron overload.